Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949445 | 0.83 | PHGDH (0.41) | KMOPPARGPPARAPPARDRXFP1 | |
| SCHEMBL947189 | 0.79 | NR1H2 (0.42) | KMOPPARGPPARAPPARDOXER1 | |
| SCHEMBL7016462 | 0.77 | F10 (0.51) | — | |
| SCHEMBL18126629 | 0.72 | PPARG (0.57) | KMOPPARGPPARAPPARDOXER1 | |
| SCHEMBL947731 | 0.72 | ALDH1A1 (0.56) | PPARG | |
| SCHEMBL22005144 | 0.72 | ACLY (0.52) | KMOPPARGPPARAPPARDRXFP1 | |
| SCHEMBL25777909 | 0.71 | PPARG (0.56) | KMOPPARGPPARAPPARDOXER1 | |
| SCHEMBL19990165 | 0.70 | KMO (0.46) | KMOPPARGPPARAPPARDRXFP1 | |
| SCHEMBL2643465 | 0.70 | RXFP1 (0.60) | RXFP1PHGDHMEN1KMT2A | |
| SCHEMBL43328 | 0.69 | KDM4E (0.66) | RXFP1PHGDHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | KMO 74/4885PPARG 1570/4885PPARA 1902/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | KMO 123/4885PPARG 1603/4885PPARA 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.